Download PDF
Thromb Haemost 1985; 54(03): 570-573
DOI: 10.1055/s-0038-1660072
Original Article
Schattauer GmbH Stuttgart

Prevention of Postoperative Deep Vein Thrombosis by a Combination of Subcutaneous Heparin with Subcutaneous Dihydroergotamine or Oral Sulphinpyrazone

Gerda Veth
*   The Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Otger J A Th Meuwissen
*   The Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands
,
Hans C van Houwelingen
**   The Department of Mathematical Statistics, State University, Utrecht, The Netherlands
,
Jan J Sixma
***   The Department of Haematology, State University, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 12 February 1985

Accepted 30 July 1985

Publication Date:
19 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In a randomized clinical trial the effect of subcutaneous heparin alone or in combination with dihydroergotamine or sulphinpyrazone in preventing postoperative deep vein thrombosis (DVT) was studied. Sodium heparin (5000 IU) was administered subcutaneously twice daily; dihydroergotamine (1/2 mg) was also administered subcutaneously twice daily, and sulphinpyrazone (400 mg) was administered orally or intravenously twice daily. Administration occurred for at least 7 days. The diagnosis DVT was made with the radiofibrinogen uptake test. 358 patients undergoing major elective abdominal surgery were allocated to three treatment groups: heparin alone (Hep), heparin + dihydroergotamine (DHE-Hep) and heparin + sulphinpyrazone (Sulph-Hep). The frequency of DVT was 14/114 in Hep, 10/115 in DHE-Hep and 20/114 in Sulph-Hep. These differences were not significant. After application of the “logistic regression” procedure of Cox (1) it turned out that the major risk factors for developing DVT were age, sex, weight, type of operation and presence of diabetes mellitus. Also a significant treatment influence was observed (p = 0.001). This treatment effect was most probably due to improvement in the DHE-Hep group.

The results in the Sulph-Hep group were not significantly different from those in the Hep group. A risk index was formulated on the basis of the above mentioned risk factors by which the chance of occurrence of DVT during heparin prophylaxis in an individual patient could be predicted. Patients that should receive additional prophylactic treatment can be defined by using this risk index.

Keywords

Deep venous thrombosis - Heparin - Dihydroergotamine - heparin - Sulphinpyrazone - heparin
 

  • References

  • 1 Cox DR. Logistic regression. In: Analysis of binary data Chapman C, and Hall H. (Eds.) London: 1970
  • 2 International Multicentre Trial. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; 2: 45-51
    PubMedGoogle Scholar
  • 3 Rieckert H. Die Pharmakodynamik des Dihydroergotamins. In: Postoperative Thromboembolie-Prophylaxe Pabst HW, Maurer G. (Eds) Schattauer Verlag; Stuttgart: 1977. pp 69-73
  • 4 Steele P, Ellis J, Genton E. Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. Am J Med 1978; 64: 441-5
    CrossrefPubMedGoogle Scholar
  • 5 Kakkar VV, Renney J TG, Nicolaides AN, Clarke MB, Friend JR. 125J-labelled fibrinogen test adapted for routine screening for deep vein thrombosis. Lancet 1970; 1: 540-5
    PubMedGoogle Scholar
  • 6 Biello DR, Mattar AG, Osei-Wusu A, Alderson PO, McNeil BJ, Siegel BA. Interpretation of indeterminate lung scintigrams. Radiology 1979; 133: 189-94
    CrossrefPubMedGoogle Scholar
  • 7 Rosenow EC, Osmundson PJ, Brown ML. Pulmonary embolism. Mayo Clin Proc 1981; 56: 161-78
    PubMedGoogle Scholar
  • 8 Walker I, Aukland P, Hirsh J, Coates G, Cockshott P, Taylor R, Hull R. The low specificity of postoperative perfusion lung scan defects. Can Med Assoc J 1981; 124: 153-8
    PubMedGoogle Scholar
  • 9 BMDP Statistical Software. University of California Press; Berkely: 1981
    Google Scholar
  • 10 Kakkar VV, Howe CT, Nicolaides AN, Renney J TG, Clarke MB. Deep vein thrombosis of the leg. Am J Surg 1970; 120: 527-30
    CrossrefPubMedGoogle Scholar
  • 11 Clayton JK, Anderson JA, McNicol GP. Preoperative prediction of postoperative deep vein thrombosis. Br Med J 1976; 2: 910-2
    CrossrefPubMedGoogle Scholar
  • 12 Lowe G DO, Osborne DH, McArdle BM, Smith A, Carter DC, Forbes CD, McLaren D, Prentic CRM. Prediction and selective prophylaxis of venous thrombosis in elective gastrointestinal surgery. Lancet 1982; 1: 409-12
    PubMedGoogle Scholar
  • 13 Hör G, Buttermann G, Theisinger W, Pabst HW. Prevention of postoperative thromboembolism by various treatments. Eur J Nucl Med 1976; 1: 197-203
    CrossrefPubMedGoogle Scholar
  • 14 Koppenhagen K, Wiechmann A, Frey E, Wenig HG, Latka H, Zühlke HV, Tank E, Hardieck J, Ernst H, Häring R. Klinisch-experimentelle Ergebnisse mit Heparin-Dihydroergotamin. Dtsch Med Wochenschr 1977; 102: 1374-9
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Browse NL, Clemenson G, Croft DN. Fibrinogen-detectable thrombosis in the legs and pulmonary embolism. Br Med J 1974; 1: 603-4
    CrossrefPubMedGoogle Scholar
  • 16 Moser KM, LeMoine JR. Is embolic risk conditioned by location of deep venous thrombosis?. Ann Intern Med 1981; 94: 439-44
    CrossrefPubMedGoogle Scholar